Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children
|ClinicalTrials.gov Identifier: NCT00751452|
Recruitment Status : Unknown
Verified January 2011 by University Hospital, Clermont-Ferrand.
Recruitment status was: Recruiting
First Posted : September 12, 2008
Last Update Posted : January 19, 2011
|Condition or disease|
30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days).
Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children|
|Study Start Date :||April 2008|
|Estimated Primary Completion Date :||September 2009|
|Estimated Study Completion Date :||September 2009|
- Citrullinemia (weekly) [ Time Frame: weekly ]
- Gastro-intestinal complications in children following allogeneic bone marrow transplantation [ Time Frame: following allogenic bone marrow transplantation ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00751452
|Contact: Lacarin Patrickemail@example.com|
|Clermont-Ferrand, France, 63003|
|Principal Investigator:||Merlin Etienne, Dr||University Hospital, Clermont-Ferrand|